Developments at Ohana Biosciences
Life sciences innovation company Flagship Pioneering today announced that first-in-category reproductive health company, Ohana Biosciences, is embarking on a fresh approach to the field of reproductive medicine with the creation of the industry's first sperm biology platform, a major shift from the traditional path of focusing on egg biology.
Since Ohana's founding in 2016, its platform has yielded product opportunities in fundamental areas of reproductive health based on insights into sperm biology. Those opportunities include improving fertility rates, reducing pregnancy complications, inherited disease, and developmental disorders, and delivering non-hormonal contraception.
Ohana - the word means "family" in Hawaiian - is led by chief executive Amber Salzman, and is based in Cambridge, Massachusetts, USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze